This study aims to assess the effect of Spinal Cord Stimulation (SCS) on the cholinergic nervous system and the glucose metabolism in the brain of patients with Parkinson’s disease (PD) and gait problems. Furthermore, this is a feasibility study that investigates the safety of this treatment and the effect on clinical gait performance of the participants.
Gait problems are common in PD and are often resistant to other treatments, including medicine. SCS has been found to improve gait, such as freezing of gait, in a small number of patients with PD. The mechanism of action is, however, unclear, and the treatment does not seem to work well in all candidates. Recently it has been implicated that cholinergic dysfunction in PD caused by degeneration of brainstem locomotor regions (such as the pedunculopontine nucleus) is involved in the control of movement initiation and body equilibrium. The cholinergic PET tracer 18FEOBV targets the vesicular acetylcholine transporter which is specific to cholinergic pre-synaptic terminals. 18F-deoxyglucose (18F-FDG) PET is a marker of regional cerebral glucose metabolic rate (by the marker of synaptic activity).
With this double-blind, randomised, placebo-controlled study, we aim to shed light on the mechanism of action of SCS with 18FEOBV and 18F-FDG PET scans. We also aim to identify imaging biomarkers at baseline that could be predictive of a favourable or a negative outcome of SCS and improve patient selection.
Contact:
Miriam Højholt Terkelsen, MD, PhD-student methoh@rm.dk
Victor Hvingelby, MD, PhD-student au340287@clin.au.dk
Supervisor: Nicola Pavese, MD, Prof. npavese@clin.au.dk